New data a boost for Johnson & Johnson and Bavarian Nordic's Ebola vaccine

The Lancet has published new data on Johnson & Johnson and Bavarian Nordic's combined vaccine against Ebola, which according to the US life science group strongly supports preventatitve use of the vaccine.

Healthcare professionals on the Ivory Coast are being vaccinated after ebola was found in the country. | Photo: Luc Gnago/Reuters/Ritzau Scanpix

Results from two new studies that have recently been published by medical journal The Lancet are a cause for celebration at Johnson & Johnson.

The studies, which concern the use of Johnson & Johnson and Bavarian Nordic's combined Ebola vaccine in Sierra Leone, show an immune response in 98 percent of participants 21 days after their second shot - the shot developed by Bavarian Nordic - but also that the vaccine is highly effective seven days after revaccination two years after the two introductory doses.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs